the unmet needs of patients with mcl who relapse after car-t
Published 1 year ago • 223 plays • Length 1:18Download video MP4
Download video MP3
Similar videos
-
2:48
outcomes of autosct, allosct & car-t cell therapy in patients with tp53-altered mcl
-
2:16
autosct vs car-t for patients with relapsed lbcl in pr: the role of total metabolic tumor volume
-
2:13
transplant and car-t for relapsed mcl
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
1:40
future directions for car t-cell therapy in mcl
-
2:12
expanding the reach of car-t
-
1:52
unmet needs in the treatment of t-cell malignancies
-
1:10
unmet needs in car-t therapy: options for patients who progress during the manufacturing process
-
1:01:36
deciphering car-t cells: exploring functional mechanisms to drive next generation immunotherapy
-
10:42
understanding mantle cell lymphoma with jia ruan, md, ph.d.
-
4:34
development and evaluation of a novel car-t cell therapy against calr mutant neoplasms
-
2:21
car t-cell therapy: what clinicians need to know about managing the aes
-
2:03
cellular kinetics of car-t & prophylactic promise
-
5:09
the evolving role of nurses in the field of car-t
-
2:02
advances in off-the-shelf car t-cells
-
1:10
unmet needs for late-stage ctcl
-
1:34
unmet needs in t-cell lymphoma
-
2:32
unmet needs in t-cell lymphoma and the importance of better understanding disease biology
-
1:18
the importance of lymphodepletion, an undervalued component of the car-t therapy cycle
-
2:30
car-t as a new standard of care in lymphoma
-
1:26
the safety and efficacy of allosct following car-t cell therapy for large b-cell lymphoma
-
6:14
horizon scan of car-t for lymphoma